{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:18:49Z","timestamp":1787843929877,"version":"build-2784847793"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Dupilumab is an anti\u2010interleukin (IL)\u20104 receptor (IL\u20104R\u03b1) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real\u2010world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups. This study evaluated dupilumab's efficacy and safety at an Australian tertiary centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All paediatric AD patients (&lt;\u200918\u2009years old) treated with dupilumab at a tertiary centre with available follow\u2010up data were retrospectively analysed. Effectiveness was measured using the Eczema Area and Severity Index (EASI), Children's Dermatology Life Quality Index (cDLQI), and Physician Global Assessment (PGA). Adverse events (AEs) were recorded. Differences in efficacy and safety between age groups (0\u20135, 6\u201311, 12\u201317\u2009years old) were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      103 patients (9.2\u2009\u00b1\u20093.8\u2009years old, 51.5% male) were analysed with a follow\u2010up of 495.3\u2009\u00b1\u2009337.3\u2009days. 95.1%, 90.1% and 66.7% of patients achieved a 50%, 75%, 90% drop in EASI (EASI\u201050, EASI\u201075, EASI\u201090). 93.4% and 94.7% of patients achieved a 6\u2010point drop in cDLQI and a 2\u2010point drop in PGA. 43.2%, 48.7% and 71.1% of patients achieved EASI \u2264\u20091, cDLQI \u2264\u20091 and PGA \u2264\u20091 respectively. Two patients discontinued dupilumab due to AEs (psoriasis flare and lichenoid drug\u2010reaction). 49 (47.6%) patients experienced AEs, with the most frequent category being ocular\u2010related (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200943). There were no statistically significant differences between age groups in the rate of achieving efficacy thresholds or in the rate of AEs for each AE category. Median time\u2010to\u2010effect for EASI\u201050\/75\/90 were 130, 140 and 291\u2009days on Kaplan\u2013Meier analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Paediatric dupilumab patients experienced significant improvements with an acceptable safety profile, independent of age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajd.70118","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:36:13Z","timestamp":1775547373000},"page":"301-308","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab's Real\u2010World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis"],"prefix":"10.1111","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5938-0292","authenticated-orcid":false,"given":"Paul Sun Woo","family":"Kim","sequence":"first","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney Australia"},{"name":"Department of Dermatology The Children's Hospital at Westmead  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Tu","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney Australia"},{"name":"Department of Dermatology The Children's Hospital at Westmead  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-4499","authenticated-orcid":false,"given":"Kelvin","family":"Truong","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney Australia"},{"name":"Department of Dermatology The Children's Hospital at Westmead  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Fong","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney Australia"},{"name":"Department of Dermatology The Children's Hospital at Westmead  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Luu","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney Australia"},{"name":"Department of Dermatology The Children's Hospital at Westmead  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barclay","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Children's Hospital at Westmead  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Wong","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney Australia"},{"name":"Department of Allergy and Immunology The Children's Hospital at Westmead  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7819-6603","authenticated-orcid":false,"given":"Li\u2010Chuen","family":"Wong","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health The University of Sydney  Sydney Australia"},{"name":"Department of Dermatology The Children's Hospital at Westmead  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.12.020"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.042"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf158"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304048"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(22)01539\u20102"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.054"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010024\u201000859\u2010y"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201001016\u20109"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010022\u201000683\u20102"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v68i1.1422"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.70031"},{"key":"e_1_2_10_14_1","unstructured":"Pharmaceutical Benefits Scheme \u201cDUPILUMAB \u201daccessed November 29 2025 https:\/\/www.pbs.gov.au\/medicine\/item\/12292Y\u201012293B\u201012294C\u201012302L\u201012310X."},{"key":"e_1_2_10_15_1","unstructured":"Department of Health Disability and Ageing \u201cSecuring cheaper medicines for people with severe eczema \u201daccessed February 2 2026 https:\/\/www.health.gov.au\/ministers\/the\u2010hon\u2010mark\u2010butler\u2010mp\/media\/securing\u2010cheaper\u2010medicines\u2010for\u2010people\u2010with\u2010severe\u2010eczema."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010019\u201000333\u20102"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19457"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13662"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.2010.09733.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2246602"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2460578"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad124"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12268"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16265"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.17927"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.04.035"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13901"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70025"},{"key":"e_1_2_10_29_1","unstructured":"Canadian Agency for Drugs and Technologies in Health \u201cDupilumab (Dupixent): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis pediatrics \u201daccessed February 3 2026 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599847\/."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2017.014"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.70118","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:33:36Z","timestamp":1787841216000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.70118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/ajd.70118"],"URL":"https:\/\/doi.org\/10.1111\/ajd.70118","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"2026-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}